The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
about
Update on developments with SGLT2 inhibitors in the management of type 2 diabetesEffects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateSHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialER stress in rodent islets of Langerhans is concomitant with obesity and β-cell compensation but not with β-cell dysfunction and diabetes.Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.Dapagliflozin: a review on efficacy, clinical effectiveness and safety.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.Sweet & low: new treatment for diabetes that may reduce blood pressure.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Dapagliflozin for the treatment of type 1 diabetes mellitus.Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis.Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
P2860
Q34198692-D2704ED6-BE9B-44CF-A331-25F5B4F8A9B0Q34273302-1C8FBB20-BB99-4D43-A8D9-F7A0E3346833Q34543009-FAEE2171-963F-4D9C-A1CF-9FB2FB276DA6Q35194026-AC4047D5-95EC-4CBA-8191-EAB945B5F5FCQ36175431-A4B39ABE-BB13-49C5-AD1C-DF1AFA2983EEQ36179371-801388B0-F839-4D58-A644-45E8BACD03B0Q36237217-F627011E-75FB-4BD1-A070-ED566C26FA2DQ36435496-2844AADC-FC21-405F-BD70-9F539CA95B2CQ36745809-4D74C464-0A4E-43DE-A0B0-EA9CE757E9CDQ37106527-C04FFC13-4ADB-46F2-9794-14463BEA315EQ37279343-7651459A-B98E-4C9C-B474-FEE754BE6A6FQ37846528-9125BEAC-ADFB-4CC9-969E-6C1FF8C00143Q37960123-90B0E6F2-ACD9-4193-B6AA-84D06E62C5DAQ37990891-F3FEA774-1E69-4926-819B-005753ACA645Q38036770-3DC610A3-3848-4611-AE55-114ED0714011Q38057810-E6D83215-C8D6-4E39-9BA5-BC6F8EF695F0Q38075117-81F911A0-999B-474F-819D-3617CFA6C9E6Q38085691-965C0173-E46A-4A89-99F8-10DE51721588Q38101387-B74FA8CE-5B0D-4837-AD66-CAFDE17AA151Q38104746-2DF21A29-28B1-4196-AC1A-7DC03BC6ECB3Q39017610-CE1773D2-8EC2-4862-8D6A-B2131438D54DQ39354776-D26CF80A-0041-4A16-A3C6-1127C0BBAFE6Q41641012-A0B8C913-CCFE-424C-B89D-F99BB4EDEA92Q43855107-78008440-4E11-4075-9587-AD2A56889BCDQ44429534-C2A4E862-5200-49CC-AB20-4BB9D6CFCE82Q48185851-D4FC3344-E0E7-49D1-AEC1-E3D118A75DD1Q48274604-8AB26DD3-660E-47C1-B49D-95123A67158CQ51034590-AC83478F-5518-41D9-957C-CF2B3CF0FCD5Q51045694-CEF869F6-275E-46A4-8312-B521EDE9637E
P2860
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@en
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@nl
type
label
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@en
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@nl
prefLabel
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@en
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@nl
P2093
P1476
The novel sodium glucose trans ...... ology in obese, diabetic rats.
@en
P2093
F R Macdonald
J M Whaley
L Westgate
R M Mayers
S M Poucher
P304
P356
10.1111/J.1463-1326.2010.01291.X
P577
2010-11-01T00:00:00Z